For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...